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Abstract
Background: Ectromelia virus (ECTV) is the causative agent of mousepox, a lethal disease of mice with similarities to human
smallpox. Mousepox progression involves replication at the initial site of infection, usually the skin, followed by a rapid
spread to the secondary replicative organs, spleen and liver, and finally a dissemination to the skin, where the typical rash
associated with this and other orthopoxviral induced diseases appears. Case fatality rate is genetically determined and
reaches up to 100% in susceptible mice strains. Like other poxviruses, ECTV encodes a number of proteins with
immunomodulatory potential, whose role in mousepox progression remains largely undescribed. Amongst these is a
secreted homologue of the cellular tumour necrosis factor receptor superfamily member CD30 which has been proposed to
modulate a Th1 immune response in vivo.
Methodology/Principal Findings: To evaluate the contribution of viral CD30 (vCD30) to virus pathogenesis in the infected
host, we have adapted a novel transient dominant method for the selection of recombinant ECTVs. Using this method, we
have generated an ECTV vCD30 deletion mutant, its corresponding revertant control virus as well as a virus encoding the
extracellular domain of murine CD30. These viruses contain no exogenous marker DNA sequences in their genomes, as
opposed to other ECTVs reported up to date.
Conclusions/Significance: We show that the vCD30 is expressed as a secreted disulfide linked trimer and that the absence
of vCD30 does not impair mousepox induced fatality in vivo. Replacement of vCD30 by a secreted version of mouse CD30
caused limited attenuation of ECTV. The recombinant viruses generated may be of use in the study of the role of the cellular
CD30-CD30L interaction in the development of the immune response. The method developed might be useful for the
construction of ECTV mutants for the study of additional genes.
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Introduction
Poxviruses are a family of large, complex shaped enveloped
dsDNA viruses of cytoplasmic replication [1]. They are subdivided
into two subfamilies, depending on whether their host are
invertebrates (Entomopoxvirinae) or vertebrates (Chordopoxvirinae).
The Chordopoxvirinae are further classified into eight genera
according to their antigenic properties and genome sequences.
Among the orthopoxviruses are several species capable of infecting
humans such as variola virus (VARV), the causative agent of
smallpox, vaccinia virus (VACV), the virus which was used to
erradicate smallpox from the human population by mass
vaccination, or monkeypox virus (MPXV), a poxvirus causing a
disease with similarities to smallpox but reduced case fatality rates
which has raised some concern about potential poxviral zoonoses
[2]. Ectromelia virus (ECTV) is a mouse specific pathogen that
belongs to the orthopoxvirus genus and causes mousepox, a severe
disease with similarities to smallpox, in susceptible mouse strains.
ECTV was used as a model for VARV infections and served to
establish the course of acute, systemic viral infections [3,4]. ECTV
usually enters its host through abrasions in the skin, where it
replicates extensively and migrates to the draining lymph node.
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5175From this initial replication site, the virus further spreads to the
central target organs, spleen and liver. A second hematogenous
spread from these sites to the skin produces the rash and pocks
which are characteristic of mousepox and other poxviral diseases.
Susceptibility to mousepox is genetically controlled and has been
mapped to the resistance to mousepox (rmp) loci which include
genes near the natural killer gene complex [5]. In susceptible
strains, such as BALB/c, the infected mice usually die from acute
liver necrosis at around day 8 to 10 postinfection, before the
secondary viremia takes place. Resistant strains, such as C57BL6,
however, develop no apparent signs of illness and viral replication
is effectively controlled by the host. Much effort has been devoted
recently to study the mechanisms of immune response against
ECTV. It has been shown that an early control of infection by
natural killer (NK) cells in resistant mice is essential to avoid
mousepox lethality [6]. The transition to an effective cytotoxic T
lymphocyte (CTL) and antibody response as well as a polarized
Th1 response have been demonstrated to be essential for survival
of the infected host and clearance of the virus [7–9].
Due to their large coding capacity, poxviruses have developed a
set of strategies to modulate their interaction with the host. Indeed,
around one third of the approximately 200 genes encoded by a
prototypical poxvirus are predicted to be directly involved in the
modulation of the host immune response. Out of these, several
were found to correspond to secreted proteins which can act as
either cytokine receptor homologues (viroceptors) or as cytokine
mimics (virokines). Examples of viroceptors include the VACV
secreted interleukin 1b (IL-1b) binding protein B15 [10,11] and
the interferon (IFN) type I binding protein B18 [12,13]. Virokines
such as the secreted VACV A39 smaphorin, which induces
cytokine production from monocytes [14] or the secreted IL-10
homologues found in orf [15] and Yaba-like disease (YLDV)
viruses [16]. Immune evasion mechanisms and their role on the
pathogenesis of poxviruses are extensively reviewed in [17–19].
One interesting example of viroceptors is the family of viral
tumor necrosis factor receptors (TNFRs) (reviewed in
[20]([21]TNF is an important proinflammatory cytokine with an
essential role in protection against invading pathogens. Not
surprisingly, most pathogens have developed means to block or
take advantage of TNF and TNF signalling in their infected hosts
(reviewed by [22]). Poxviruses have developed a family of secreted
TNFRs which are thought to act in vivo by binding to TNF and
blocking its activity. Indeed, most poxviral species have been
predicted to encode at least one active member of this family,
underscoring the importance of the TNF-TNFR axis in the
control of viral infections. Viral TNFRs belong to two different
families. The YLDV 2L protein-like proteins bind to TNF but
share no sequence similarity to cellular TNFRs or to other cellular
genes of known or unknown function [23,24]. The cytokine
response modifier B (CrmB), CrmC, CrmD and CrmE proteins,
which are differentially expressed by poxviral species all contain a
variable number of the cysteine rich domains (CRDs) which define
the superfamily of cellular TNFRs. All of them have been
described to bind and inhibit TNF and/or lymphotoxin in vitro
[25–29]. A fifth member of this viral protein family containing two
CRDs was described as a viral CD30 homologue (vCD30) [30,31].
This protein is most similar to the murine CD30 protein and was
found to interact not with TNF but with CD30 ligand (CD30L,
CD153), a distinct member of the TNF superfamily which is the
only described ligand for cellular CD30.
ECTV vCD30 was described as a 12-kDa, secreted late viral
protein. It binds murine CD30L with an affinity of 0.66 nM and is
able to block the binding of CD30L to its cell surface receptors.
Moreover, vCD30 was found to be able to induce reverse signalling
through the CD30L expressed on the surface of freshly isolated
human neutrophils [31]. This is a unique property among viral
TNFR superfamily members, which are thought to act as decoy
receptors, blocking the interaction of a soluble cytokine with its
cognate receptor. Soluble CD30L, however, has not been described
so far and therefore vCD30 must be acting at the cell surface either
interfering with the interaction of CD30 with CD30L and or
inducing signalling through CD30L. Finally, vCD30 was found to
inhibit the activation of IFN-c production by splencocytes in a
mixed lymphocyte reaction and to block a Th1 but not a Th2-like
inflammatory response in vivo [31]. Therefore, vCD30 wasproposed
toactasanimportantdeterminant ofmousepoxpathogenesisinvivo.
To test this hypothesis, we wished to construct a recombinant
ECTV lacking the vCD30 gene. The generation of recombinant
poxviruses relies on homologous recombination within the cell
between viral sequences present in the replicating virus genomes
and viral DNA sequences present in a transfected plasmid.
Construction of deletion mutants in poxviruses can be achieved
by disruption or replacement of the open reading frame of interest
witha selectablemarker.Inspite ofbeingan easyandfast toachieve
method, the introduction of a very active new transcriptional unit
may affect expression levels of neighbouring genes [32] and the
production of a foreign marker may affect virus replication in vivo.
Alternatively, deletion can be achieved by transient-dominant
selection of the recombinant viruses and, although technically more
complex, the results obtained are more trustable since the deletion
of the gene is less likely to cause a phenotype not mediated by the
gene of interest. In addition, this method for the deletion of a gene
facilitates the production of a revertant control virus in which a full-
length gene is reinserted into the same locus [33].
As the frequency of the recombinant viruses formed upon
homologous recombination is low, recombinant viruses have to be
distinguished from the parental viruses, which constitute the vast
majority of the virus progeny. With this purpose, a variety of
genetic markers have been used in the past, including colour
selection, by using b-galactosidase, b-glucuronidase or EGFP, and
specific drug selection, such as neomycin or mycophenolic acid.
Although the presence of a coloured marker is easier to recognise,
the presence of a selectable marker that confers resistance to a
drug facilitates selection of the recombinant viruses. A combina-
tion of both criteria was developed to obtain VACV recombinants
by using the EGFP and the puromycin acetyltransferase (pac) gene
from Streptomyces alboniger, which confers resistance to the inhibitor
of protein synthesis puromycin [34].
In this study, we have adapted this method to efficiently
generate ECTV deletion mutants lacking any foreign sequence in
their genomes. Additionally, the method allows the consecutiev
modification of recombinant viruses without the need for
additional selectable markers at each recombination step. This
method has been used to study the role of vCD30 during
mousepox progression.
Results and Discussion
A transient dominant selection method for the
generation of recombinant ECTV
The study of the pathogenesis of orthopoxviruses lacking
particular genes involved in the evasion of the immune response
provides important information not only on the role of these genes
in the virus context but also on the host antiviral defence
mechanisms [35]. We have adapted the method described by
Sanchez-Puig et al. [34] for the generation of recombinant
ECTVs. The principle of the method (Figure 1A) consists on the
simultaneous infection of cells with ECTV and transfection with a
Role of vCD30 in Mousepox
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and 39 flanking regions of the gene to be deleted and a
downstream expression cassette that allows for selection
(Figure 1B). Homologous recombination between viral DNA
sequences present in the recombinant plasmid and genomic
ECTV DNA produces recombinant viruses formed by a single
cross-over event that inserts the complete plasmid into the ECTV
genome. The intermediate viral species transiently expresses the
selectable markers, EGFP, which can be visualized under the
fluorescence microscope and pac, which confers resistance to
puromycin. This intermediate virus can be isolated by allowing the
virus to replicate during several passages and to be amplified in the
presence of the antibiotic, which causes cells to detach and does
not allow plaque assays. A subsequent plaque assay on cell
monolayers in the absence of puromycin selection enables picking
of plaques which appear green under UV-light examination
(Figure 1C). In a second step, perfomed on cell monolayers in the
absence of selection, another recombination event occurs,
resulting in the resolution of the intermediate virus and leading
to the formation of either a virus lacking the targeted gene or to
Figure 1. Transient dominant selection for the generation of ECTV recombinant viruses. A. Schematic representation of the
recombination events between the viral genome and the plasmid as well as the phenotypes of intermediate and final viruses obtained during the
procedure. B. Representation of the plasmid pMS35 used for the generation of the ECTVDCD30 virus. The vCD30 locus and the primers used for
amplification of the flanking regions are indicated. C. Flowchart of the main steps in the generation of the ECTVDCD30 virus.
doi:10.1371/journal.pone.0005175.g001
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cloned into the recombinant plasmid is similar, the proportion of
mutant and wild-type viruses should be similar. At this stage, it is
possible to isolate viral plaques that have lost the selectable marker
and test them in order to identify a deletion mutant virus and to
distinguish it from wild-type viruses. Finally, the desired
recombinant virus is purified by successive plaque purification.
The production and selection of a revertant virus is achieved
exactly in the same way, but in this case the cells are infected with
the deletion mutant, instead of the wild-type virus, and transfected
with a plasmid containing a full-length wild-type copy of the gene
and its flanking regions. In the first step, an intermediate virus,
harbouring the fully integrated recombinant plasmid and both the
wild type and deleted versions of the gene, is selected by serial
passage in the presence of puromycin. In the second step, virus
plaques expressing a wild type gene are isolated by plaque assay in
the absence of puromycin.
The initial vector described by Sanchez-Puig et al. [34] was
optimised for the use with ECTV by replacement of the synthetic
early/late promoter that was driving the expression of EGFP for the
stronger synthetic late promoter [36], which appears to workbetter in
ECTV infection (N. Bryant and A. Alcami, unpublished results).
Additionally, in order to achieve good levels of pac expression, we
cloned the IRES of the encephalomyocarditis virus between the
EGFP and pac genes which allowed the bicistronic mRNA transcript
to be translated from the 59 end and from the IRES sequence, so that
the pac gene was also under the control of the strong synthetic late
promoter. This selectable cassette was transferred to pUC118, so that
the flanking regions of the genes of interest could be cloned upstream
of it. This final universal vector for the construction of ECTV
recombinant viruses was named pMS30. Further optimisation steps
of the method were required to generate recombinant ECTVs and
included adjusting the concentration and time of addition of
puromycin so that the growth of the recombinant viruses over the
wild-type background was favoured (data not shown). The necessary
number of puromycin selection steps was estimated at four. Titration
of the viruses present after each puromycin selection cycle showed
that the percentage of green virus increased until the fourth step and
was constant after that (data not shown). The percentage of green
ECTV never reached 100%, most likely due to the continuous
resolutionoftheintermediatepuromycin-resistantviruscausedbythe
presence of direct repeats and the occurance of a second
recombination event rendering both deletion mutant and wild-type
viruses white (data not shown).
Circular plasmids containing the full-length VACV genome that
could be stably propagated in E. coli and converted to infectious
virus in mammalian cells were more recently developed [37]. The
authors proposed that this would make it possible to modify or
delete VACV genes or add foreign DNA in a bacterial system,
eliminating the need for the plaque purification procedures
employed up to date, providing a more efficient method for high
throughput analyses. This procedure was recently adapted to study
the role of five proteins with potential immunomodulatory
properties of the attenuated strain Modified Vaccinia virus Ankara
(MVA) [38], which is widely used as a safe recombinant vaccine
vector. Although the method allowed the rapid generation and
analysis of deletion mutants, the viruses generated still contained
foreign marker sequences. Thus, this approach may be more
useful for screening analyses or generation of large recombinant
virus libraries in different poxviruses, including ECTV.
Generation of recombinant ECTV lacking the vCD30 gene
The method described was used for the construction of
recombinant ECTVs which are schematically depicted in
Figure 2A. In the first place, an ECTV deletion mutant in the
vCD30 gene (ECTVDCD30) was obtained. To control for
unwanted mutations elsewhere in the genome of ECTVDCD30
and for specificity of any observed phenotype, this deletion mutant
was used to generate a revertant virus (ECTVRevCD30) in which
a copy of the vCD30 gene is reinserted into its locus. Finally, to
compare the properties of the vCD30 with those of the cellular
secreted form of CD30, we introduced a copy of the region
encoding the secreted domain of murine CD30 under the control
of the ECTV vCD30 promoter into the orignal vCD30 locus,
generating ECTVmCD30.
As shown in Figure 2B, all recombinant viruses grew with
similar kinetics to the parental ECTV on BSC-1 cell monolayers,
showing that lack of vCD30 or expression of murine CD30 does
not affect viral replication in cell culture.
Only a few recombinant ECTVs have been generated and
characterized so far. Deletion of the ECTV homologue of the
VACV host range gene K1L was achieved by insertion of the E.
coli guanine phosphoribosyltransferase (Eco-gpt) gene and selection
of the recombinant virus in the presence of mycophenolic acid
[39]. Infections of mice with the K1L-lacking ECTV yielded a
pathogenesis pattern indistinguishable from wild-type, suggesting
that the ECTV homologue of VACV K1L is not important for
ECTV replication and spread in vivo. An ECTV thymidine kinase
(TK) minus recombinant obtained by insertion of the b-
galactosidase gene into the viral TK gene showed decreased
virulence possibly due to a decreased replicative capacity in target
cells in vivo [40]. An ECTV virus lacking the p28 protein, which
has been later found to act as an E3 ubiquitin ligase [41] was
obtained by insertion of the Eco-gpt gene [42] and found to be
attenuated in vivo. This attenuation was attributed to a failure of
the virus to replicate in macrophage lineage cells, impairing viral
spread from the skin to its target organs [43]. The same method
was used to obtain an ECTV mutant lacking the IL-18 binding
protein, p13 [44]. Although this virus showed an increased NK
cell activity, only a modest attenuation in terms of viral titers was
described. The main criticism to these studies is the absence of a
revertant virus, in which the wild type gene is reinserted into the
viral genome, to control for inadvertent mutations present
elsewhere in the deletion mutant. All the referred recombinant
ECTVs were generated by insertion of a selectable marker into the
gene of interest and therefore the resulting phenotype may not
necessarily be the only consequence of the absence of the targeted
gene. The more recently described deletion mutant of the ECTV
IFN-c binding protein was obtained by a transient dominant
selection method using Eco-gpt [45]. In this case, a revertant virus
was generated. However, the deletion mutant still contained an
exogenous LacZ in its genome. For the deletion of the type I IFN
binding protein encoded by EVM166, insertion of the EGFP gene
marker was used [46]. Again, a revertant virus was generated, but
lacked the EGFP present in the virus which it was compared to.
Thus, we believe that the method presented here for the
generation of recombinant ECTVs is of benefit for the study of
the virus in vivo, as the viruses to be compared will differ only in the
genes of interest, containing no exogenous sequences in their
genomes. Additionally, viral genomes may be sequentially
modified using the same approach, as selctable markers are not
retained and can therefore be reused.
The secreted vCD30 interacts specifically with CD30L and
forms disulfide-mediated trimers
To study the role of ECTV vCD30, we first expressed and
purified a His-tagged vCD30 protein (vCD30His) using a
baculovirus expression system. By non-reducing SDS-PAGE we
Role of vCD30 in Mousepox
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trimers in solution (not shown). We next screened this protein for
potential binding partners among the members of the TNF
superfamily of murine origin. Previous reports had shown that the
vCD30Fc fusion protein did not bind to human or murine TNFa
(TNFSF2), Lta (TNFSF1), LTb (TNFSF3), LTab complexes or
the ligands for CD40 (TNFSF5), 4-IBB (TNFSF9), OX40
(TNFSF4), Fas (TNFSF6) or CD27 (TNFSF7) in competition by
scintillation proximity assay (FlashPlate) [30,31]. We confirmed by
surface plasmon resonance (SPR) with a BIAcore X biosensor this
lack of interaction for the purified vCD30His protein and
extended it to the murine RANK L (TNFSF 11), TWEAK
(TNFSF 12), APRIL (TNFSF 13), LIGHT (TNFSF 14) proteins
(Figure 3). Thus, we extended previous data to a larger set of 15
TNFSF members and concluded that CD30L (TNFSF 8) is the
sole binding partner of vCD30 (Figure 3 and not shown).
We next tested whether the endogenous vCD30 protein was
secreted as a trimer during ECTV infection of cells. Western blot
analyses of supernatants of BSC-1 cells infected with parental
ECTV or ECTVRevCD30 and harvested at late times post-
infection showed a band of approximately 12 kDa which was
absent from samples from ECTVDCD30 infected cells. This band
migrated at approximately 38 kDa in the absence of a reducing
agent, showing that the vCD30 synthesised during infection forms
disulfide bridge-mediated multimers most likely corresponding to
trimers (Figure 4A). As expected, the samples obtained from the
ECTVRevCD30-infected cells showed similar expression levels of
vCD30. A control western blot revealed similar amounts of the late
secreted ECTV protein CrmD in the samples of all infected cells
(Figure 4B). It has been shown that cellular TNFRs undergo
trimerization upon or prior to ligand binding [47,48], which is
important for intracellular signalling. The vCD30 may have
Figure 2. ECTV vCD30 is not essential for virus growth in cell culture. A. Representation of the genomic structure of the different ECTV
generated showing the vCD30 and the adjacent E12 loci. B. Single-step growth curves of the indicated viruses on BSC-1 cells. Shown are means of
triplicate samples for each time point.
doi:10.1371/journal.pone.0005175.g002
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conformation mediated by covalent bonds which may act as a
more potent ligand for the cognate cellular receptor or for
displacement of the cellular CD30-CD30L interaction. In this
regard it has been shown that the related viral TNFR CrmD from
ECTV is capable of forming disulfide-linked complexes which can
bind their ligand [28]. The VARV secreted TNFR CrmB was also
found to form disulfide mediated dimers [49]. Similarly, it has
been found that the ECTV secreted IFN-c binding protein forms
tetramers which are critical for antagonizing IFN-c activity [50].
Role of vCD30 in mousepox
To study the contribution of vCD30 to ECTV virulence, we
first infected resistant C57BL6 or susceptible BALB/c mice
subcutaneously in the footpad with different doses of the
mentioned wild type or recombinant viruses. In the case of
C57BL6 mice, doses of 10
4,1 0
5 and 10
6 pfu per animal were
tested and no differences were observed in weight loss or signs of
illness over the 30 day observation period, with all mice resisting to
infection but showing swelling of the inoculation site, indicative of
active viral replication (not shown). Resistant mice are able to
mount an efficient Th1 response in the presence of vCD30 and
therefore were not expected to succumb to infection with the
ECTVDCD30 mutant. A similar set of experiments was perfomed
using susceptible, BALB/c mice, which are characterised by
developing a poor Th1 response to ECTV. As before, signs of
illness, weight loss and footpad swelling were scored daily during a
35 day post-inoculation period. After subcutaneous infection of
susceptible BALB/c mice with doses of 1, 10, 100 and 1000 pfu
per animal, an approximate LD50 of 10 pfu and a mean time to
death of 11 days post-infection were observed in all groups (not
shown). This indicated that vCD30 is not required for mousepox
induced lethality or disease severity. The vCD30 has been shown
to be an effective inhibitor of Th1-like inflammatory responses in
vivo [31] suggesting that it may be compromising an effective
antiviral response during mousepox. Although it remains to be
Figure 3. ECTV vCD30 ligand screening. Sensorgram showing binding of mTNFSF8 (CD30L) injected at 50 nM to purified vCD30 coupled to a
CM5 sensor chip by SPR analysis. TNFSF10 (pink line), TNFSF11 (cyan line), TNFSF12 (red line) and TNFSF14 (green line) injected at 100 nM each did
not show interaction.
doi:10.1371/journal.pone.0005175.g003
Figure 4. ECTV vCD30 forms disulfide linked trimers. Western blot analysis using anti vCD30 (A) or anti CrmD (B) antibodies of supernatants
from mock-infected BSC-1 cells (M) or cells infected with ECTV (E), ECTVDCD30 (D) or ECTVRevCD30 (R).
doi:10.1371/journal.pone.0005175.g004
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infected mice was quicker or more potent in terms of activation,
these possible differences were not able to overcome infection. In
this regard it would be interesting to determine the LD50 of the
different viruses in mouse strains of intermediate susceptibility.
Expression of the soluble murine CD30 did not have any effect in
any of the situations examined.
The natural infection route for ECTV is through abrasions in
the skin and therefore subcutanous inoculation is possibly the most
physiologically relevant model. However, oronasal transmission is
also possible. Therefore, we next tested the intranasal inoculation
route. The resistant C57BL6 strain shows an enhanced suscepti-
bility to ECTV when infected intranasally. When C57BL6 mice
were inoculated intranasally with high doses of parental ECTV
virus (10
4,1 0
5 and 10
6 pfu per animal), all infected mice died after
a 9 to 12 day period. No significant differences were observed
among the animals infected with the different recombinant viruses
(not shown). Intranasal infection of susceptible BALB/c mice with
doses of 1, 10 or 100 pfu per animal showed no significant
differences between ECTV or ECTVDCD30-infected mice, with
the LD50 at approximately 100 pfu and mean time to death of 12
days post-infection. As shown in Figure 5, ECTV replication in the
bronchiolar epithelia was readily detected by day 7 post-infection
in animals infected with either parental, ECTVDCD30 or
ECTVRevCD30 viruses. Concomitant spleen necrosis and
replication in this target organ was also detected by immunohis-
tochemistry (IHC). Expression of vCD30 in vivo was similarly
confirmed by IHC (Figure 5). Infection with ECTV mCD30
appeared to result in a slightly attenuated disease at these low
doses, and to confirm this difference a second experiment using
groups of 15 susceptible mice was performed (Figure 6). Indeed, a
modest reduction of mortality in the case of ECTV mCD30
infected mice as compared to the parental ECTV, ECTVDCD30
or control ECTVRevCD30 infected mice was observed. The
reason for this slight attenuation is currently unknown and may
relate to differences in the specific activity of the vCD30 as
compared to the mCD30.
Thus, we have shown that the ECTV vCD30 is not a major
determinant of mousepox induced mortality in susceptible
BALB/c mice and that deletion of the gene does not affect the
resistant host’s ability to overcome the viral infection. It remains
to be established whether the quantity or the quality of the
immune response against the invading virus is affected in the
absence of the vCD30 protein and whether viral replication is
compromised under these conditions. In this context it is
important to mention that CD153 (CD30L) was shown to be
important in the augmentation of a Th1 response capable of
producing IFN-c against Mycobacterium bovis bacillus Calmette-
Guerin (BCG) infection in mice, with the number of bateria
being significantly higher in the organs of CD153 knockout mice
than in wild type mice [51]. Additionally, other roles for the
CD30-CD153 pair with potential impact on mousepox devel-
opment have been shown such as modulation of B-cell responses
[52,53] and memory T cell generation [54], suggesting other
aspects of the immune response against ECTV that will have to
be studied in the future to determine the mode of action of the
vCD30.
Although it has been considered that secreted viral proteins
with immunomodulatory potential may act as essential determi-
nants of viral pathogenesis, few such proteins have been analysed
in detail during ECTV infection. Thus, deletion of the ECTV
IL-18 binding protein produced better NK cell activation and
higher levels of type I cytokines during infection, but had no
significant impact on viral replication in vivo [44]. In contrast,
d e l e t i o no ft h et y p eII F N[ 4 6 ]o rt y p eI II F Ns o l u b l er e c e p t o r s
[ 4 5 ]h a da ni m p o r t a n ti m p a c to nb o t hi m m u n er e s p o n s ea n d
host’s survival, as exemplified by the difference in LD50 in
susceptible mice in both cases. It will be of interest to establish
the relative contribution of other secreted immunmodulators
such as the TNF and chemokine receptor CrmD, the
complement inhibitory protein or the chemokine inhibitory
protein among others.
The vCD30 was originally described in cowpox virus and
ECTV strains, although the sequencing of new poxviral genomes
has found vCD30 orthologues which are predicted to be active in
horsepox virus [55], a probable predecessor of VACV [56] and
the W83, but not the W84 strain of deerpox virus [57]. In any
case, the presence of vCD30 orthologues is restricted to a few
poxvirus species, suggesting either a common evolutionary history
or an unknown common host-related selective pressure for all of
these viral species. We have generated a valuable tool for the
determination of the role of the vCD30 during poxvirus-caused
infection in their hosts. Additionally, we expect that the
recombinant viruses that we have generated may be used to
analyse the role of the cellular CD30-CD30L interaction during
acute viral infections in vivo.
Materials and Methods
Cells and viruses
The reference ECTV strain used was ECTV Naval.Cam
(complete genome sequence available at www.poxvirus.org). This
virus was derived from the original ECTV Naval strain obtained
from Dr. Mark Buller (Universiy of St. Louis, USA) by isolating
virus from a spleen sample of an infected BALB/c mouse by three
consecutive rounds of plaque purification on BSC-1 cell
monolayers. ECTVs were grown in BSC-1 cells. For infection of
mice, virus stocks were purified by centrifugation through a 36%
sucrose cushions as described [58].
Figure 5. Absence of ECTV vCD30 does not affect viral spread
or replication in vivo. Lung (top row, L) and spleen (S) samples from
representative uninfected (NI) or intranasally infected BALB/c mice at
day 7 post-infection were analysed by IHC for virus replication and
vCD30 expression, as indicated. H&E analysis shows extensive necrosis
of spleen tissue of infected animals.
doi:10.1371/journal.pone.0005175.g005
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The plasmid pMS30 was constructed for expression of EGFP
under a synthetic late promoter followed by an IRES cassette for
expression of the puromycin acetyltransferase gene from the same
transcript. Details of the sequence and generation of the plasmid
are available upon request. The 59 flanking region of the CD30
gene was amplified with oligonucleotides CD30-6 (59-
GCGGAATTCCTGATAGACAGTTGCCTATTAAAGTG)
and CD30-7 (59-GCGGGATCCGATGTACTCCTGATACCA-
CAACAAAG), and the 39 flanking region of CD30 was amplified
with oligonucleotides CD30-8 (59-GCGGGATCCGATGTATA-
TACTAGGCAGGTTACG) and CD30-9 (59-GCGCTGCAG-
CATCGATAAATTGACCAAGTTACAC). Both flanking re-
gions were cloned sequentially into EcoRI- and PstI-digested
pMS30 to give plasmid pMS35, which was used for the generation
of ECTVDCD30. Both flanking regions and the intervening CD30
gene were PCR-amplified with oligonucleotides CD30-6 and
CD30-9 to generate the plasmid pMS38 that was used for
reinsertion of the CD30 gene into the ECTVDCD30 genome and
construction of ECTVRevCD30. To construct ECTVmCD30, a
new 39flanking region for vCD30 which contained the putative
promotor of the vCD30 gene but not its initiator ATG was
amplified with oligonucleotides CD30-9 and CD30-11 (59-
GCGGGATCCGCTATTTAATACATCTAATATATG) into
BamHI- and PstI-digested pMS35, giving plasmid pAH6. The
sequence coding for the predicted extracellular domain of the
murine CD30 (M1 to T281) was PCR-amplified with oligonucle-
otides MmCD30-7 (59-CGCGGATCCAGCATGAGCGCCC-
TACTCACCGCAGC) (including a consensus Kozak sequence)
and MmCD30-8 (59- GCGGGATCCTATGTTCCCGTGGA-
CAATGGAGAGGTG) (including a stop codon) and cloned into
BamHI-digested pAH6, giving plasmid pAH10. The plasmid
PBMGNeo mCd30 full length used as a template was kindly
provided by Dr. E. Podack (University of Miami, USA). All
plasmids were sequenced to confirm absence of unwanted
mutations. To generate the recombinant ECTVs, BSC-1 cells were
transfected with pMS35, pMS38 or pAH10 using Genejammer
(Stratagene) following the manufacturer’s recommendations and
infected at low moi (0.1 or 0.01 pfu/cell) with the corresponding
ECTVs. Two days after transfection/infection, the intermediate
single-crossover recombinant viruses in which the complete plasmid
has been inserted into the ECTV genome were selected by three to
five consecutive infection rounds in the presence of 10 mg/ml
puromycin and monitored by EGFP expression. Puromycin was
added at 4 hpi and maintained for a 48 h period, after which virus
was harvested and used as inoculum for the following selection
round. Recombinant viruses (ECTVDCD30, ECTVRevCD30 and
ECTVmCD30) were finally selected by successive plaque purifica-
tion of white plaques in the absence of puromycin and screening by
a CD30-specific PCR to identify the desired recombinant viruses.
The genomic structure of all recombinant viruses obtained was
analyzed by PCR amplification of the vCD30 and flanking genes,
and by Southern blot to confirm absence of large genome
rearrangements that may not have been noticed by PCR (not
shown).
Expression and purification of recombinant ECTV vCD30
protein
The vCD30 gene without the sequence coding for its predicted
amino terminal signal peptide was amplified using oligonuclotides
CD30-17 (59-CGCGCTAGCACGTGTCCTAATGATTAC-
TATCTTG) and CD30-18 (59-GCGCTCGAGTCATGAT-
GAGTATTTATGATAACAAAG) and ECTV DNA as a tem-
plate. The PCR product was cloned into NheI- and XhoI-digested
pRSETA (Invitrogen) to generate plasmid pAH14. The vCD30
was expressed as an N-terminal 66His tag fusion protein in BL21
DE3 E.coli using plasmid pAH14H and purified by Ni-NTA
(Qiagen) affinity chromatography under denaturing conditions
following the manufacturer’s guidelines. The purified protein was
used to generate polyclonal rabbit anti-vCD30 sera. To express a
C-terminally 66His-tagged vCD30 in a eukaryotic vector, the
complete vCD30 ECTV gene was amplified using oligos CD30-3
(59-CGCAAGCTTGGATCCATGAAGATGAATACTATCTT-
TTTATC) and CD30-4 (59-CGCGCGGCCGCTGATGAG-
TATTTATGATAACAAAG) and cloned into HindIII/NotI-
digested pBac1(Novagen), generating plasmid pMS2. This was
used to generate the recombinant baculovirus AcMS2 using
the Novagen BacPAK system following the manufacturer’s
instructions.
Biomolecular interaction analysis by SPR
Cytokine binding specificity was determined using a BIAcore X
biosensor (Biacore, Uppsala, Sweden). For the ligand screening
experiments, purified recombinant vCD30 protein was amine-
coupled to CM5 chips to a level of aprox. 5000 RU (5000 pg/
mm
2). Recombinant murine TNFSFs were then injected at a
100 nM or 200 nM concentration in HBS-EP buffer (10 mM
Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant
P20; pH 7.4) at a flow rate of 10 ml/min and association and
dissociation monitored. The surface was regenerated after each
injection using 10 mM glycine-HCl pH 1.5. All Biacore sensor-
grams were analysed using BIAevaluation 3.2 software. Bulk
refractive index changes were removed by subtracting the
reference flow cell responses and the average response of a blank
injection was subtracted from all analyte sensorgrams to remove
systematic artifacts.
Infection of mice
Female 6–8 weeks old BALB/c OlaHsd or C57BL/6 mice
(Harlan) were anesthesized using isofluorane and infected
subcutaneously in the left hind footpad or intranasally with
10 ml of semipurified virus. Mice were housed in ventilated racks
(Tecniplast) under biological safety level 3 containment facilities.
Monitoring of infected animals was performed daily. Animals were
weighed, scored for clinical signs of illness (scores ranging from 0
for healthy animals to 4 for severely diseased animals) and footpad
swelling measured where appropriate. These experiments have
been approved by the Biological Safety Committee of the Centro
de Investigacio ´n en Sanidad Animal (CISA, INIA, Valdeolmos,
Madrid) and animals are housed and handled according to local
and EU legal requirements.
Figure 6. Expression of murine soluble CD30 attenuates mousepox development. Groups of 15 susceptible BALB/c mice were infected
intranasally with 100 pfu each of the indicated viruses and scored daily for signs of illness and weight loss. Survival rates are shown on the bottom
panel.
doi:10.1371/journal.pone.0005175.g006
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Lung and spleen samples from infected mice were removed
aseptically, fixed in 10% buffered formalin solution and embedded
in paraffin wax. For structural and immunohistochemical analysis,
sections (3 mm) were cut and stained with H&E or processed for
immunohistochemical techniques. To detect virus or ECTV
vCD30 protein, formalin fixed serial sections were incubated with
polyclonal rabbit anti-VACV antibody from a VACV-infected
rabbit [59] or the polyclonal rabbit anti-CD30 antibody obtained
in our laboratory, respectively. Secondary goat anti-rabbit
immunoglobulin G (Dako) was detected using an avidin-
peroxidase-complex kit (PIERCE, Thermo Scientific) and 3,39-
diaminobenzidine tetrahydrochloride (Sigma) following the man-
ufacturer’s instructions. The slides where counterstained with
Mayer’s haematoxylin, dehydrated, and mounted with DPX
mountant (Surgipath). Specific primary antibodies were replaced
by phosphate buffered saline or normal goat serum in negative
control sections.
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